Cantor Fitzgerald Estimates ADMA Biologics FY2025 Earnings

ADMA Biologics Inc (NASDAQ:ADMA) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of ADMA Biologics in a research report issued on Wednesday, June 25th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of $0.61 for the year, down from their prior forecast of $0.72. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share. Cantor Fitzgerald also issued estimates for ADMA Biologics’ FY2026 earnings at $0.89 EPS.

ADMA has been the topic of a number of other research reports. Raymond James Financial raised their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. Wall Street Zen lowered ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th.

ADMA Biologics Stock Performance

ADMA opened at $18.40 on Thursday. The firm has a market capitalization of $4.39 billion, a P/E ratio of 21.65 and a beta of 0.47. The stock’s 50 day moving average price is $20.69 and its two-hundred day moving average price is $18.76. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. ADMA Biologics has a 12-month low of $10.21 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The business’s quarterly revenue was up 40.2% compared to the same quarter last year. During the same period last year, the business earned $0.08 EPS.

Institutional Trading of ADMA Biologics

Several institutional investors have recently bought and sold shares of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock valued at $865,000 after buying an additional 645 shares in the last quarter. Cetera Investment Advisers boosted its stake in ADMA Biologics by 1.3% in the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock valued at $1,002,000 after buying an additional 670 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in ADMA Biologics by 1.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock valued at $954,000 after buying an additional 700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ADMA Biologics by 1.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 711 shares in the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in ADMA Biologics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 746 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 10,000 shares of the business’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director now owns 478,194 shares of the company’s stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence P. Guiheen sold 7,779 shares of the business’s stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the sale, the director now directly owns 114,830 shares in the company, valued at approximately $2,333,345.60. This represents a 6.34% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 464,621 shares of company stock valued at $9,644,269. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.